Prime Medicine Files 8-K
Ticker: PRME · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1894562
| Field | Detail |
|---|---|
| Company | Prime Medicine, Inc. (PRME) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
TL;DR
Prime Medicine filed a standard 8-K, no new news.
AI Summary
Prime Medicine, Inc. filed an 8-K on October 24, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Prime Medicine, Inc. to the SEC, without disclosing new material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would impact risk.
Key Players & Entities
- Prime Medicine, Inc. (company) — Registrant
- October 24, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 60 First Street Cambridge, MA 02139 (address) — Principal executive offices
FAQ
What is the purpose of this 8-K filing for Prime Medicine, Inc.?
The 8-K filing on October 24, 2024, serves to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Prime Medicine, Inc.
In which state was Prime Medicine, Inc. incorporated?
Prime Medicine, Inc. was incorporated in Delaware.
What is the address of Prime Medicine, Inc.'s principal executive offices?
The address of Prime Medicine, Inc.'s principal executive offices is 60 First Street, Cambridge, MA 02139.
Does this filing disclose any specific new material events or financial results?
No, this filing primarily indicates routine reporting requirements and does not disclose specific new material events or financial results.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-10-24 08:04:24
Filing Documents
- prme-20241024.htm (8-K) — 27KB
- a10-24x2024xesgctpressrele.htm (EX-99.1) — 23KB
- 0001628280-24-043500.txt ( ) — 182KB
- prme-20241024.xsd (EX-101.SCH) — 2KB
- prme-20241024_lab.xml (EX-101.LAB) — 22KB
- prme-20241024_pre.xml (EX-101.PRE) — 13KB
- prme-20241024_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 24, 2024, Prime Medicine, Inc. issued a press release entitled "Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31 st Annual Congress." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press Release, dated October 24 , 202 4 , furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 24, 2024 Prime Medicine, Inc. By: /s/ Keith Gottesdiener Name: Keith Gottesdiener, M.D. Title: President and Chief Executive Officer